Clinical Trial Detail

NCT ID NCT04456699
Title Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal adenocarcinoma

Therapies

Bevacizumab + Olaparib

Bevacizumab + Fluorouracil

Olaparib

Age Groups: adult senior

No variant requirements are available.